Literature DB >> 16816378

Disabled-2 heterozygous mice are predisposed to endometrial and ovarian tumorigenesis and exhibit sex-biased embryonic lethality in a p53-null background.

Dong-Hua Yang1, Zia Fazili, Elizabeth R Smith, Kathy Qi Cai, Andres Klein-Szanto, Cynthia Cohen, Ira R Horowitz, Xiang-Xi Xu.   

Abstract

Disabled-2 (Dab2) is a phosphoprotein involved in cellular signal transduction and endocytic trafficking. The expression of Dab2 is frequently lost or suppressed in several epithelial tumors, and studies of its cellular function and growth suppressive activity when re-expressed in cancer cells led to the suggestion that Dab2 is a tumor suppressor. A role for Dab2 in epithelial cell positioning organization was derived from study of knockout mice: homozygous deletion of dab2 results in early embryonic lethality due to the disorganization of the primitive endoderm, the first epithelium in early embryos. We now report that dab2 heterozygous mice develop uterine hyperplasia and ovarian preneoplastic morphological changes at a high frequency. Crossing into a p53(-/-) background unexpectedly produced few female dab2(+/-):p53(-/-) mice, while the male dab2(+/-):p53(-/-) were born at the expected Mendelian frequency. The tumor-prone phenotype of dab2(+/-) mice provides additional support for a role of human Dab2 as a tumor suppressor, and the sex-biased embryonic lethality suggests a genetic interaction between p53 and dab2 genes in female mice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16816378      PMCID: PMC1698752          DOI: 10.2353/ajpath.2006.060036

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  46 in total

1.  Disabled-2 exerts its tumor suppressor activity by uncoupling c-Fos expression and MAP kinase activation.

Authors:  J He; E R Smith; X X Xu
Journal:  J Biol Chem       Date:  2001-05-18       Impact factor: 5.157

2.  Disabled-2 colocalizes with the LDLR in clathrin-coated pits and interacts with AP-2.

Authors:  S M Morris; J A Cooper
Journal:  Traffic       Date:  2001-02       Impact factor: 6.215

Review 3.  Precursor lesions of ovarian epithelial malignancy.

Authors:  K M Feeley; M Wells
Journal:  Histopathology       Date:  2001-02       Impact factor: 5.087

4.  The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade. DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2.

Authors:  J Zhou; J T Hsieh
Journal:  J Biol Chem       Date:  2001-05-22       Impact factor: 5.157

5.  High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice.

Authors:  V Stambolic; M S Tsao; D Macpherson; A Suzuki; W B Chapman; T W Mak
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

6.  The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway.

Authors:  B A Hocevar; A Smine; X X Xu; P H Howe
Journal:  EMBO J       Date:  2001-06-01       Impact factor: 11.598

7.  Disabled-2 (Dab2) mediates transforming growth factor beta (TGFbeta)-stimulated fibronectin synthesis through TGFbeta-activated kinase 1 and activation of the JNK pathway.

Authors:  Barbara A Hocevar; Celine Prunier; Philip H Howe
Journal:  J Biol Chem       Date:  2005-05-12       Impact factor: 5.157

8.  Restoration of positioning control following Disabled-2 expression in ovarian and breast tumor cells.

Authors:  Z Sheng; W Sun; E Smith; C Cohen; Z Sheng; X X Xu
Journal:  Oncogene       Date:  2000-10-05       Impact factor: 9.867

9.  Cytosolic adaptor protein Dab2 is an intracellular ligand of endocytic receptor gp600/megalin.

Authors:  A V Oleinikov; J Zhao; S P Makker
Journal:  Biochem J       Date:  2000-05-01       Impact factor: 3.857

Review 10.  The p53 tumor suppressor gene frequently is altered in gynecologic cancers.

Authors:  A Berchuck; M F Kohler; J R Marks; R Wiseman; J Boyd; R C Bast
Journal:  Am J Obstet Gynecol       Date:  1994-01       Impact factor: 8.661

View more
  13 in total

1.  Migrating with myosin VI.

Authors:  Beatrice Knudsen
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

2.  BRCA1-mediated signaling pathways in ovarian carcinogenesis.

Authors:  Tejaswita M Karve; Xin Li; Tapas Saha
Journal:  Funct Integr Genomics       Date:  2011-09-02       Impact factor: 3.410

3.  Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter.

Authors:  Adèle Hannigan; Paul Smith; Gabriela Kalna; Cristiana Lo Nigro; Clare Orange; Darren I O'Brien; Reshma Shah; Nelofer Syed; Lindsay C Spender; Blanca Herrera; Johanna K Thurlow; Laura Lattanzio; Martino Monteverde; Meghan E Maurer; Francesca M Buffa; Jelena Mann; David C K Chu; Catharine M L West; Max Patridge; Karin A Oien; Jonathan A Cooper; Margaret C Frame; Adrian L Harris; Louise Hiller; Linda J Nicholson; Milena Gasco; Tim Crook; Gareth J Inman
Journal:  J Clin Invest       Date:  2010-07-01       Impact factor: 14.808

4.  Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations.

Authors:  Chen Wu; Xiaoping Miao; Liming Huang; Xu Che; Guoliang Jiang; Dianke Yu; Xianghong Yang; Guangwen Cao; Zhibin Hu; Yongjian Zhou; Chaohui Zuo; Chunyou Wang; Xianghong Zhang; Yifeng Zhou; Xianjun Yu; Wanjin Dai; Zhaoshen Li; Hongbing Shen; Luming Liu; Yanling Chen; Sheng Zhang; Xiaoqi Wang; Kan Zhai; Jiang Chang; Yu Liu; Menghong Sun; Wei Cao; Jun Gao; Ying Ma; Xiongwei Zheng; Siu Tim Cheung; Yongfeng Jia; Jian Xu; Wen Tan; Ping Zhao; Tangchun Wu; Chengfeng Wang; Dongxin Lin
Journal:  Nat Genet       Date:  2011-12-11       Impact factor: 38.330

5.  Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics.

Authors:  Amy L Gross; Robert J Kurman; Russell Vang; Ie-Ming Shih; Kala Visvanathan
Journal:  J Oncol       Date:  2010-04-27       Impact factor: 4.375

6.  Immunobiology of human mucin 1 in a preclinical ovarian tumor model.

Authors:  R A Budiu; E Elishaev; J Brozick; M Lee; R P Edwards; P Kalinski; A M Vlad
Journal:  Oncogene       Date:  2012-09-10       Impact factor: 9.867

7.  Loss of GATA4 and GATA6 expression specifies ovarian cancer histological subtypes and precedes neoplastic transformation of ovarian surface epithelia.

Authors:  Kathy Qi Cai; Corrado Caslini; Callinice D Capo-chichi; Carolyn Slater; Elizabeth R Smith; Hong Wu; Andres J Klein-Szanto; Andrew K Godwin; Xiang-Xi Xu
Journal:  PLoS One       Date:  2009-07-31       Impact factor: 3.240

8.  Technical challenges and limitations of current mouse models of ovarian cancer.

Authors:  Kenneth Garson; Lisa F Gamwell; Elizabeth Mg Pitre; Barbara C Vanderhyden
Journal:  J Ovarian Res       Date:  2012-11-29       Impact factor: 4.234

9.  Differential requirement for Dab2 in the development of embryonic and extra-embryonic tissues.

Authors:  Robert Moore; Kathy Qi Cai; Wensi Tao; Elizabeth R Smith; Xiang-Xi Xu
Journal:  BMC Dev Biol       Date:  2013-10-29       Impact factor: 1.978

10.  miR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in lung cancer.

Authors:  L Du; Z Zhao; X Ma; T-H Hsiao; Y Chen; E Young; M Suraokar; I Wistuba; J D Minna; A Pertsemlidis
Journal:  Oncogene       Date:  2013-09-16       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.